Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Related articles

VOLUME 29 , ISSUE 4 ( April, 2025 ) > List of Articles

Original Article

Bacteremia Caused by Rare NFGNB in the ICU: A Single-center Experience

Parikshit S Prayag, Prasad Rajhans, Nilesh Mahale, Sampada A Patwardhan, Pruthu N Dhekane, Rajeev N Soman, Deepak Sethia, Mousami Dalvi, Surabhi Dhupad, Surabhi Tyagi, Rasika S Joshi, Abhishek Deshmukh, Madhavi Wavhal, Priyamvada Sharma, Amrita P Prayag

Keywords : Bacteremia, Burkholderia, Gram-negative bacteria, Non-fermenters

Citation Information : Prayag PS, Rajhans P, Mahale N, Patwardhan SA, Dhekane PN, Soman RN, Sethia D, Dalvi M, Dhupad S, Tyagi S, Joshi RS, Deshmukh A, Wavhal M, Sharma P, Prayag AP. Bacteremia Caused by Rare NFGNB in the ICU: A Single-center Experience. Indian J Crit Care Med 2025; 29 (4):345-351.

DOI: 10.5005/jp-journals-10071-24940

License: CC BY-NC 4.0

Published Online: 31-03-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Introduction: Amongst the non-fermenting gram-negative bacteria (NFGNB), Pseudomonas (P.) and Acinetobacter species predominate the landscape. However, less common NFGNB such as Burkholderia, Stenotrophomonas, Achromobacter, Ralstonia and Elizabethkingia species, amongst others, are assuming increasing importance. We describe a single-center experience of bacteremia caused by rare NFGNBs in an Indian intensive care unit (ICU). Materials and methods: A retrospective study of adult patients with bacteremia caused by rare NFGNB in the ICU. Results: Of the total 205 cases, Burkholderia (B.) species (43.4%, n = 89) were the commonest, followed by Stenotrophomonas species (20.4%, n = 42). The bacteremia was related to an indwelling catheter in 42.9 % of the patients. The median duration of hospitalization preceding the bacteremia was 16 days. Except for B. Achromobacter and Aeromonas species, meropenem showed high rates of resistance. Overall, cotrimoxazole, levofloxacin and minocycline were the most effective antibiotics active in vitro; with some differences noted specific to different organisms. The overall day 28 mortality was 34.1%. On multivariate analysis, the presence of shock (p = 0.008, CI: 1.188–5.052) and receipt of steroids (p = 0.015, CI: 1.032–3.891) were significantly associated with mortality. Conclusions: This is one of the largest studies from India, describing the landscape of NFGNB causing bacteremia in the ICU. Our study shows that these infections are acquired late during the course of hospitalization, have limited therapeutic options, and can be associated with significant mortality. Implementation of stringent infection control practices is needed to reduce this threat.


PDF Share
  1. Bannore N, Kapadia F, Hegde A. Difficult to treat gram-negative bacteria—the Indian scenario. Curr Infect Dis Rep 2024;26(2):69–77. DOI: 10.1007/s11908-024-00834-y.
  2. Indian Council of Medical Research (ICMR). Annual report (January 2023 to December 2023) of the Antimicrobial Resistance Research & Surveillance Network (AMRSN). Division of epidemiology and communicable diseases. 2023. [online] Available from: https://www.icmr.gov.in/icmrobject/uploads/Documents/1725536060_annual_report_2023.pdf. [Last accessed March, 2025].
  3. Ganesan V, Sundaramurthy R. Elizabethkingia meningoseptica Infections: A case series from a tertiary hospital in South Tamil Nadu. Indian J Crit Care Med 2022;26(8):958–960. DOI: 10.5005/jp-journals-10071-24292.
  4. Saran S, Gurjar M, Garg A, Sahu C, Bhaskar B, Mishra P, et al. Uncommon non-fermenting Gram-negative bacillary bacteraemia in ICU patients. Infectious Diseases 2020;52(5):372–375. DOI: 10.1080/23744235.2020.1716991.
  5. Geiger AM, Hogardt M, Heesemann J. Burkholderia/Stenotrophomonas. Contrib Microbiol 2001;8:20–34. DOI: 10.1159/000060400.
  6. Weber DJ, Rutala WA, Blanchet CN, Jordan M, Gergen MF. Faucet aerators: A source of patient colonization with Stenotrophomonas maltophilia. Am J Infect Control 1999;27(1):59–63. DOI: 10.1016/s0196-6553(99)70077-5.
  7. Looney WJ. Role of Stenotrophomonas maltophilia in hospital-acquired infection. Br J Biomed Sci. 2005;62(3):145–154; quiz 1 p following 154. DOI: 10.1080/09674845.2005.11732702.
  8. Wang N, Tang C, Wang L. Risk Factors for acquired stenotrophomonas maltophilia pneumonia in intensive care unit: A systematic review and meta-analysis. Front Med (Lausanne) 2022;12;8:808391. DOI: 10.3389/fmed.2021.808391.
  9. Xu C, Lin Q, Zhao Y, Zhu G, Jiang E, Li S, et al. Clinical characteristics and risk factors of Aeromonas bloodstream infections in patients with hematological diseases. BMC Infect Dis 2022;22(1):303. DOI: 10.1186/s12879-022-07277-7.
  10. Rhodes KA, Schweizer HP. Antibiotic resistance in Burkholderia species. Drug Resist Updat 2016;28:82–90. DOI: 10.1016/j.drup.2016.07.003.
  11. Wang Y, He T, Shen Z, Wu C. Antimicrobial resistance in stenotrophomonas spp. Microbiol Spectr. 2018;6(1). DOI: 10.1128/microbiolspec. ARBA-0005-2017.
  12. Varshini MK, Ganesan V, Sundaramurthy R, Rajendran T. Risk factors and clinical outcomes of stenotrophomonas maltophilia infections: Scenario in a Tertiary Care Center from South India. Indian J Crit Care Med 2022;26(8):935–937. DOI: 10.5005/jp-journals-10071- 24288.
  13. Lin IF, Lai CH, Lin SY, Lee CC, Lee NY, Liu PY, et al. In vitro and in vivo antimicrobial activities of vancomycin and rifampin against elizabethkingia anophelis. Int J Mol Sci 2023;24(23):17012. DOI: 10.3390/ijms242317012.
  14. Isler B, Kidd TJ, Stewart AG, Harris P, Paterson DL. Achromobacter Infections and Treatment Options. Antimicrob Agents Chemother. 2020;64(11):e01025–e010220. DOI: 10.1128/AAC.01025-20.
  15. Huang CH, Jang TN, Liu CY, Fung CP, Yu KW, Wong WW. Characteristics of patients with Burkholderia cepacia bacteremia. J Microbiol Immunol Infect 2001;34(3):215–219. PMID: 11605815.
  16. Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant gram-negative infections. Clin Infect Dis 2024:ciae403. DOI: 10.1093/cid/ciae403.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.